News on Hepatitis continually updated from thousands of sources around the net.
2 hrs ago | WNYC-AM New York
The launch of Sovaldi, the $1,000-a-day pill for hepatitis C, is shaping up as the most successful ever.
Trending on the Topix Network
3 hrs ago | Information Technology
Heplisav [Hepatitis B vaccine, 1018 ISS immunostimulatory oligonucleotide with HBsAg ] is Dynavax Technologies' adjuvanted pipeline vaccine candidate that guards adults against acute and chronic infections caused by all known strains of HBV, with a particular emphasis on protecting adults that have failed to achieve seroconversion from the ... (more)
7 hrs ago | Newsday
The stock market slipped Wednesday after rallying for six straight days as investors worked through another round of quarterly earnings reports from U.S. companies.
7 hrs ago | ABC News
The stock market slipped Wednesday, after rising for six straight days, as investors worked through another round of quarterly earnings reports from U.S. companies.
10 hrs ago | BioMed Central
The risk of hepatocellular carcinoma increases in chronic hepatitis B surface antigen carriers who often have concomitant increase in the levels of benzo[alpha]pyrene-7,8-diol-9,10-epoxide -DNA adduct in liver tissues, suggesting a possible co-carcinogenesis of Hepatitis B virus and benzo[alpha]pyrene in HCC; however the exact mechanisms involved ... (more)
14 hrs ago | Aidsmap
Our award-winning series of patient information booklets. Each title provides a comprehensive overview of one aspect of living with HIV.
15 hrs ago | Customer Interaction Solutions
The global market has the potential to grow to a value of $18.6 billion by 2019, more than tripling the 2012 market value of $5.8 billion Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape.
Welcome to the Gilead Sciences' first quarter 2014 earnings conference call. I would now like to turn the call over to Patrick O'Brien, Vice President of Investor Relations.
Ms Sarah Opendi, the state minister for health, said the money is required for purchase of drugs for treatment and vaccines for the next two years.
Diego M Flichman , Jorgelina L Blejer , Beatriz I Livellara , Viviana E Re , Sonia Bartoli , Juan A Bustos , Claudia P Ansola , Susana Hidalgo , Martin E Cerda , Alicia E Levin , Adriana Huenul , Victoria Riboldi , Elena MC Trevino , Horacio J Salamone , Felix A Nunez , Robert J Fernandez , Juan F Reybaud and Rodolfo H Campos ... (more)
Ottawa-based comedian Mike MacDonald makes his first Ha!ifax Comedy Fest appearance at the opening gala Wednesday night at Casino Nova Scotia.
Gilead Sciences Inc , which ignited a fierce debate over prescription drug prices, said its new $1,000 hepatitis C pill generated quarterly sales of $2.27 billion, helping the company's quarterly net profit nearly triple.
Gilead Sciences Inc., AT&T Inc. and Amgen Inc. were among the stocks actively trading Tuesday evening, with shares of Gilead climbing after handily beating Wall Street's quarterly earnings and revenue expectations and reporting a sales surge for its new hepatitis C treatment.
When a particularly effective medical treatment also turns out to be particularly expensive, it creates a quandary for the insurers and patients who foot the bill.
This week's issue of the New England Journal of Medicine evaluates the use of ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.
Enanta Pharmaceuticals, Inc. , a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that AbbVie, Enanta's collaboration partner for ABT-450, has submitted a New Drug Application to the U.S. Food and Drug Administration seeking approval for an ... (more)
Warmuth had some tough times to get through; 17 years ago he was diagnosed with hepatitis C, a virus that attacks the liver.